tbuckley/cabot-search huggingface dataset:
Abstract 17230: Early Continuous EEG Biomarkers Predicts Neurologic Outcome in Post-cardiac Arrest Rats
Authors: Joosuk Oh, Tulasi Jinka, Xiaodan Ren, William C Stacey, Robert W Neumar
Journal: Circulation (2015)

Introduction: Hypothermic targeted temperature management (TTM) has greatly improved post-cardiac arrest patient outcomes, but also makes prognostication more difficult. In this study, we tested the hypothesis that early continuous EEG biomarkers are associated with neurologic outcome in post-cardiac arrest rats treated with normothermic and hypothermic TTM. Methods: Male rats were instrumented for continuous telemetric EEG (cEEG) recording and then subjected to 8-minute asphyxia cardiac arrest. Eight rats that achieved ROSC underwent either normothermic or hypothermic TTM (37 ± 0.5 °C or 33 ± 0.5 °C) for 24 hours and cEEG monitoring up to 72 hours. Quantitative EEG analysis determined the power density of delta (0.1-4 Hz), theta (4-8 Hz), alpha (8-13 Hz) and sigma (13-18 Hz) frequency bands in all 10 second windows. The mean spectral power and Spearman correlation with time for the first 12 hours after return of spontaneous circulation (ROSC) were calculated and correlated with best neurologic function score (NFS) and survival with good NFS (NFS ≥ 450 out of 500). Results: Over all rats tested, the mean delta band power in the first 12 hours after ROSC was inversely correlated with best neurologic function score and associated with poor outcome (Table and Figure). There was no statistical difference in other frequency bands. Similar findings were present when stratifying into normothermic and hypothermic treatment groups. Conclusions: This study suggests that, the early power density of delta frequency bands from cEEG is a potential predictor of neurologic outcome in a mixed population of rats treated with normothermic and hypothermic TTM.
Discrimination and Calibration of Clinical Prediction Models
Authors: Ana Carolina Alba, Thomas Agoritsas, Michael Walsh, Steven Hanna, Alfonso Iorio, P. J. Devereaux, Thomas McGinn, Gordon Guyatt
Journal: JAMA (2017)

Accurate information regarding prognosis is fundamental to optimal clinical care. The best approach to assess patient prognosis relies on prediction models that simultaneously consider a number of prognostic factors and provide an estimate of patients' absolute risk of an event. Such prediction models should be characterized by adequately discriminating between patients who will have an event and those who will not and by adequate calibration ensuring accurate prediction of absolute risk. This Users' Guide will help clinicians understand the available metrics for assessing discrimination, calibration, and the relative performance of different prediction models. This article complements existing Users' Guides that address the development and validation of prediction models. Together, these guides will help clinicians to make optimal use of existing prediction models.
Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): A phase 1 dose escalation study of regorafenib (Reg) combined with paclitaxel (PTX) (REPEAT study)
Authors: S. Schokker, S.O. Van der Woude, R.A.A. Mathot, M.F. Bijlsma, M.G.H. Van Oijen, C.J.A. Punt, H.W.M. Van Laarhoven
Journal: Annals of Oncology (2017)
Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts)
Authors: R. Palmero, Á. Taus, M. Majem Tarruella, S. Viteri, E. Carcereny Costa, J. Garde, E. Felip Font, C. Cassidy, D. Dix, N. Karachaliou, R. Rosell
Journal: Annals of Oncology (2017)
Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma
Authors: L. Liu, K. Köchert, H. Seidel, J. Garcia-Vargas, B.H. Childs, G. Follows, K. Bouabdallah, M. Dreyling, C. Peña
Journal: Annals of Oncology (2017)
Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
Authors: Thomas Gevaert, Rodolfo Montironi, Antonio Lopez-Beltran, Geert Van Leenders, Yves Allory, Dirk De Ridder, Frank Claessens, Mark Kockx, Murat Akand, Steven Joniau, George Netto, Louis Libbrecht
Journal: Seminars in Cancer Biology (2017)
Estimated costs of treatment-related adverse events (TRAEs) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the checkmate 141 trial
Authors: M. Venkatachalam, S. Bobiak, J.W. Shaw, I. Santi, M. Contente, B. Korytowsky, D.D. Stenehjem
Journal: Annals of Oncology (2017)
Abstract 13828: Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin
Authors: Iris Lin, Ruslan Horblyuk, Jack Mardekian, Sang Hee Park, Shital Kamble, Melissa Hamilton, Younos Abdulsattar, William Petkun, Joseph Menzin, Gregory Y Lip
Journal: Circulation (2016)

Introduction: With the availability of four non-Vitamin K antagonist oral anticoagulants (NOACs) for patients with non-valvular atrial fibrillation (NVAF), insights into how these medications perform in ‘real-world’ settings, particularly among heart failure (HF) patients with increased risk for stroke and bleeding events, would be helpful. This study compared bleeding risk among newly anticoagulated NVAF patients, overall and in an HF subgroup. Methods: Using Humedica de-identified EHR data, newly anticoagulated adult NVAF patients with treatment initiation (index) between 2013 and 2015 were identified. Based on index prescription, patients were assigned to apixaban, rivaroxaban, dabigatran, and warfarin cohorts and followed until the earliest of drug switch, bleeding event (major or clinically-relevant non-major), last encounter, or 180 days post-index. For the HF subgroup, patients had to have an HF diagnosis in the 12 months pre-index. EHR prescription data did not allow accounting for discontinuation. Cox proportional hazard analysis was used to estimate bleeding hazard ratios (HR) for each NOAC compared to warfarin, adjusting for age, sex, region, stroke risk, and baseline comorbidities. Results: A total of 118,300 NVAF patients were selected, of which 17,127 were HF patients. Mean age ranged from 71.9 for dabigatran to 74.6 for warfarin. Mean CHADS 2 score was similar across cohorts. Overall, initiation of apixaban (HR: 0.78; 95% CI: 0.73-0.82) and dabigatran (HR: 0.71; 95% CI: 0.66-0.77) was associated with statistically significant lower risk of bleeding compared to warfarin, while rivaroxaban (HR: 1.09; 95% CI: 1.04-1.13) was associated with higher risk of bleeding compared to warfarin. Results were similar in the HF subgroup with the risk of bleeding lower for apixaban (HR: 0.78; 95% CI: 0.67-0.90) and dabigatran (HR: 0.67; 95% CI: 0.54-0.82) and higher for rivaroxaban (HR: 1.19; 95% CI: 1.07-1.32). Conclusion: Among NVAF patients, both overall and those with HF, initiating treatment with apixaban and dabigatran was associated with significantly lower risk of any bleeding event compared to initiating warfarin, whereas initiating with rivaroxaban was associated with higher bleeding risk compared with warfarin.
MRSA in case di riposo nei Paesi Bassi dal 1989 al 1998: un serbatoio in crescita?
Authors: W Goettsch, E Geubbels, W J B Wannet, M G R Hendrix, J H T Wagenvoort, A J de Neeling
Journal: Eurosurveillance (2000)

La prevalenza di isolamento di Staphylococcus aureus meticillino-resistenti (MRSA) nelle case di riposo nei Paesi Bassi nel 1998 e stata maggiore di quella riscontrata dal 1989 al 1997. L’aumento della prevalenza di MRSA potrebbe portare a una colonizzazione all’esterno delle case di riposo. Uno studio della prevalenza di MRSA nelle case di riposo con inizio verso la meta del 2000, prendera in considerazione il possibile ruolo delle case di riposo come serbatoio di infezioni ospedaliere MRSA.
Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma
Authors: A.H. Boekhout, M. Hauptmann, A.J.M. van den Eertwegh, G.A.P. Hospers, J.W.B. de Groot, M.J.B. Aarts, E. Kapiteijn, A.J. Ten Tije, D. Piersma, W.H.J. Kruit, K.P.M. Suijkerbuijk, F.W.P.J. Berkmortel, G. Vreugdenhil, R.H. Koornstra, E. Fiets, M. Lees, K.J.M. Janssen, L.V. van den Poll-Franse, C.U. Blank
Journal: Annals of Oncology (2017)

Background: After the introduction of ipilimumab, an anti-CTLA-4 monoclonal antibody, durable, long term survival has become a possibility for a subgroup of advanced melanoma patients. Since ipilimumab is a relatively novel drug there are limited data on the long-term physical, psychological, and social functioning of these patients. This study will evaluate the long-term physical and psychosocial performances and the information needs of advanced melanoma survivors who have been treated with ipilimumab. Trial design: This is a prospectively enrolling, multicentre cohort study. Objectives: To assess health-related quality of life (HRQoL), anxiety, depression, fatigue, fear of cancer recurrence, sexual health and generic health status in patients with advanced melanoma who have survived at least 2 years after ipilimumab treatment (without subsequent other systemic therapies) as compared with healthy controls, and to describe the melanoma-specific HRQoL, impact of cancer, social functioning and information needs in patients with advanced melanoma who have survived at least 2 years after ipilimumab treatment. Patients and healthy control population: Patients with advanced (stage IV or unresectable stage III) melanoma who survived at least 2 years and were treated with ipilimumab between 2011 and 2015 in 14 hospitals in the Netherlands are included. The patient population consists of 3 treatment groups based on time since ipilimumab treatment: 24 to < 36 months, ≥ 36 to < 48 months and ≥ 48 months post-ipilimumab treatment. The healthy control population will be selected from ‘Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES)’. PROFILES contains a reference cohort of more than 2000 healthy individuals and is designed to be representative of the Dutch-speaking population in the Netherlands. Measurements: The primary and secondary study outcomes will be measured by questionnaires, at 3 time-points in patients 24 to < 36 months and at 1 time-point in patients ≥ 36 months post-ipilimumab treatment. The primary outcome, HRQoL will be assessed with the European Organisation for Research and Treatment of Cancer quality of life questionnaire-C30 (EORTC QLQ-C30). Clinical trial identification: Date of release: November 2016 Legal entity responsible for the study: Netherlands Cancer Institute Funding: Bristol-Myers Squibb Disclosure: A.H. Boekhout: Employee of Bristol-Myers Squibb. M. Lee, KJM Janssen: Employee of and receiving stock from Bristol-Myers Squibb, during the conduct of the study. All other authors have declared no conflicts of interest.
GW28-e0260 Predictive value of big endothelin-1 on cardiovascular events in patients with myocardial infarction younger than 35 years old
Authors: Bingyang Zhou, Xi Zhao, Ping Qing, Chenggang Zhu, Naqiong Wu, Yuanlin Guo, Ying Gao, Geng Liu, Qian Dong, Jianjun Li
Journal: Journal of the American College of Cardiology (2017)
IMpassion031: A phase III study comparing neoadjuvant atezolizumab (atezo) vs placebo in combination with anthracycline/nab-paclitaxel (nab-pac)–based chemotherapy in early triple-negative breast cancer (eTNBC)
Authors: E.A. Mittendorf, C.H. Barrios, N. Harbeck, K.H. Jung, D. Miles, S. Saji, H. Zhang, A-N. Duc, S. Rafii, C. Lai
Journal: Annals of Oncology (2017)
Short-term clinical outcome from a randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer: Japan Clinical Oncology Group study JCOG1006
Authors: Y. Takii, K. Komori, M. Shiozawa, M. Ohue, Y. Nishimura, S. Ikeda, N. Takiguchi, T. Kobatake, H. Ike, T. Sato, N. Tomita, J. Mizusawa, H. Katayama, Y. Shimada, Y. Kanemitsu
Journal: Annals of Oncology (2017)
Bioinformatic estimate of biomarker-positive populations in genomics-driven trials using precision trial designer (PTD)
Authors: L. Mazzarella, G. Melloni, A. Guida, G. Curigliano, E. Botteri, A. Esposito, M. Kamal, C. Le Tourneau, L. Riva, P. Pelicci
Journal: Annals of Oncology (2017)
Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients
Authors: M.C. Garassino, E. Cortesi, F. Grossi, R. Chiari, H.J. Soto Parra, S. Cascinu, F. Cognetti, D. Turci, L. Blasi, C. Bengala, E. Mini, E.E. Baldini, T. Gamucci, G.L. Ceresoli, P. Antonelli, E. Vasile, M. Pagano, M. Macerelli, A. Lagroscino, F. De Marinis
Journal: Annals of Oncology (2017)

Background: Nivolumab is the first checkpoint inhibitor approved for the treatment of non-Squamous non-small cell lung cancer (non-Sq-NSCLC). In previous studies, a greater clinical benefit was shown in current and former smokers than in never smokers and in EGFR mutated patients (pts). Nevertheless, no data are available from a real-world setting. Here we report the data from Italian expanded access program (EAP) in the never smoker pts and EGFR mutated pts. Methods: Nivolumab was provided upon physicians' request for pts aged ≥18 years who had relapsed after a minimum of one prior systemic treatment for stage IIIB/stage IV non-Sq-NSCLC. Nivolumab 3 mg/kg was administered intravenously every 2 weeks for ≤24 months. Pts included in the analysis received ≥1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events. Results: Of 1588 patients with non-Sq-NSCLC, 305 (19%) were never smokers and, among 1455 pts evaluable for EGFR mutation, 102 (7%) were positive. In the never smoker group, EGFR status was available for 287 pts, with 51 (19%) who harbored an activating EGFR mutation. Among never smokers, with a median follow-up (FU) of 7.0 months (0.1-20.3) and a median of 7 doses (1-38), the objective response rate (ORR), the disease control rate (DCR) and the median overall survival (OS) were 9%, 42% and 10.0 months (8.1-11.9), respectively. Among all EGFR positive pts, with a median FU of 5.5 months (0.1-20.9) and a median of 6 doses (1-40), the ORR, DCR and median OS were 9%, 30% and 8.3 months (2.2-14.4), respectively. In the never smoker group, EGFR positive pts had 2% ORR, 26% DCR and 5.6 months (3.4-7.8) of median OS. However, it should be considered that these pts had poorer prognostic factors (ECOG performance status, brain metastasis) at baseline. Conclusions: These preliminary results represent the first real-life data regarding the efficacy of nivolumab in special subpopulations, including never smokers and EGFR positive pts. Even if ORR and OS seem lower than in general population, due to lack of alternatives and good safety profile, nivolumab should be considered as a therapeutic option. Clinical trial identification: CA209 966 Legal entity responsible for the study: Lucio Crinò Funding: None Disclosure: M.C. Garassino: Potential conflict of interest with: Bristol-Myers Squibb, Roche, AstraZeneca. H.J. Soto Parra: Advisory board of: AstraZeneca, Bristol-Myers Squib, Lilly, MSD, Merck Sharp & Dohme AG. F. De Marinis: Potential COI with: Boehringer Ingelheim, MSD, AstraZeneca, BMS, Celgene, Novartis, Pfizer, Roche/Genentech, Pierre-Fabre All other authors have declared no conflicts of interest.
GW28-e0752 Update on New Simple Imaging Test Identifying Correctly the Heart Failure Patients who do not Need In-patient Admission or will have Short Hospital Stay if Admitted
Authors: Thach Nguyen, Khanh Duong, Vien T. Truong, Thai Ba Anh Minh, Luong Ngoc Tuyet Nhi, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2017)
Abstract 17366: Intraoperative Ventricular Tachycardia Ablation During Left Ventricular Assist Device Implant in Patients With Medically Refractory Ventricular Tachycardia
Authors: Ayhan Yoruk, David T Huang, Burr W Hall, Spencer Rosero, Saadia Sherazi, Leway Chen, Valentina Kutyifa, H. Todd Massey, Mehmet K Aktas
Journal: Circulation (2016)

Introduction: Patients with advanced heart failure proceeding to LVAD implant require a multidisciplinary approach to their care. These patients often require multimodal therapies for control of th...
The impact of Oncotype DX breast cancer assay results on clinical practice: A UK experience
Authors: V.E. Crolley, H. Marashi, S.K.R. Rawther, M. Parton, J. Graham, A. Vinayan, S. Sutherland, A. Rigg, A. Wadhawan, C. Harper-Wynne, E. Spurrell, H. Bond, F. Raja, J. King
Journal: Annals of Oncology (2017)
Mapping Selection within Drosophila melanogaster Embryo’s Anatomy
Authors: Irepan Salvador-Martínez, Marta Coronado-Zamora, David Castellano, Antonio Barbadilla, Isaac Salazar-Ciudad
Journal: Molecular Biology and Evolution (2017)

We present a survey of selection across Drosophila melanogaster embryonic anatomy. Our approach integrates genomic variation, spatial gene expression patterns, and development with the aim of mapping adaptation over the entire embryo's anatomy. Our adaptation map is based on analyzing spatial gene expression information for 5,969 genes (from text-based annotations of in situ hybridization data directly from the BDGP database, Tomancak et al. 2007) and the polymorphism and divergence in these genes (from the project DGRP, Mackay et al. 2012). The proportion of nonsynonymous substitutions that are adaptive, neutral, or slightly deleterious are estimated for the set of genes expressed in each embryonic anatomical structure using the distribution of fitness effects–alpha method (Eyre-Walker and Keightley 2009). This method is a robust derivative of the McDonald and Kreitman test (McDonald and Kreitman 1991). We also explore whether different anatomical structures differ in the phylogenetic age, codon usage, or expression bias of the genes they express and whether genes expressed in many anatomical structures show more adaptive substitutions than other genes. We found that: 1) most of the digestive system and ectoderm-derived structures are under selective constraint, 2) the germ line and some specific mesoderm-derived structures show high rates of adaptive substitution, and 3) the genes that are expressed in a small number of anatomical structures show higher expression bias, lower phylogenetic ages, and less constraint.
Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.
Authors: Jennifer R. Brown, Paolo Ghia, Jeffrey Alan Jones, Andrew Pettitt, Jeff Porter Sharman, Loic Ysebaert, Stephan Stilgenbauer, Yeonhee Kim, Terry Newcomb, Nai-Shun Yao, Richard R. Furman
Journal: Journal of Clinical Oncology (2016)

7531 Background: Idelalisib (IDELA) is effective in the treatment of patients (pts) with relapsed/refractory (R/R) CLL. Nonetheless, pts may discontinue (D/C) IDELA due to progressive disease (PD) or adverse events (AEs). In this post hoc analysis, we examined the outcomes of pts with R/R CLL who D/C IDELA and the relationship of these outcomes to IDELA exposure. Methods: Data were pooled for pts treated with IDELA + rituximab (NCT01539512, n = 110), IDELA monotherapy (NCT01539291, extension study), and IDELA + ofatumumab (NCT01659021, n = 173). Time-dependent endpoints, including time to next therapy (TTNT), time to PD (TTPD), and time to death (TTD), were calculated from the dates of permanent IDELA D/C. Kaplan-Meier analysis was used to estimate overall survival (OS) from the date of randomization. Subgroup analyses of OS were performed using the integrated safety data set. Results: Of 283 pts in the safety population, 124 (44%) remained on IDELA, 28 (10%) D/C due to PD, and 131 (46%) D/C for non-PD reasons (AEs, n = 87; “other” reasons, n = 44 [death, n = 7; study withdrawal, n = 21; physician’s decision, n = 14; other, n = 2]). Clinical outcomes for these D/C groups (excluding “other”) are presented in the table. Pts who D/C IDELA due to PD also had longer median IDELA exposure (11 vs 8 mo) than those who D/C due to AEs. Conclusions: Pts who were required to discontinue IDELA due to AEs survived no longer than those required to discontinue due to PD. OS was similar among pts who D/C IDELA, regardless of reason for D/C. Analyses of patient characteristics, type of PD and dose intensities associated with IDELA D/C, as well as outcomes based on timing of D/C due to AEs (early vs late), are ongoing. Clinical trial information: NCT01539512, NCT01539291, NCT01659021. IDELA Ongoing (n = 124) D/C IDELA Due to PD (n = 28) D/C IDELA Due to AE (n = 87) Baseline -17p/TP53mut, n (%) 46 (37.1) 15 (53.6) 36 (41.4) Median (95% CI) OS, mo NR (NR, NR) 18.8 (15.5, NR) 20.9 (15.8, NR) OS at 24 mo, % 100 44.4 33.4 TTPD n = 0 n = 28 n = 41 Median (95% CI), mo N/A N/A 0.8 (0.0, 8.7) TTNT n = 0 n = 7 n = 15 Median (95% CI), mo N/A 0.9 (0.2, 3.7) 4.6 (1, 20.7) TTD n = 0 n = 9 n = 32 Median (95% CI), mo N/A 2.4 (0.1, 9.9) 0.7 (0.1, 9.1) NR = not reached.
Abstract 12000: Altered Vascular Elasticity Reflected Vascular Endothelial Dysfunction and Elevated Galectin-3 Using Novel Brachial Artery Vascular Volume Elastic Modulus With Automated Oscillometric Approach
Authors: Keiichiro Yoshinaga, Yuuki Tomiyama, Satoshi Fujii, Saori Nishio, Noriki Ochi, Chietsugu Katoh, Mamiko Inoue, Mutumi Nishida, Keisuke Takeuchi, Yoichi M Ito, Nagara Tamaki
Journal: Circulation (2015)

Introduction: Simple vascular function measurements are desirable for atherosclerosis risk assessments. Recently, we developed a novel modality of automated oscillometric method to measure a brachial artery’s vascular elastic modulus (V E ) and reported that V E is uninfluenced by blood pressure. Galectin-3 (Gal-3) expressed in endothelial cells regulates vascular fibrosis and is a molecular determinant of vascular stiffness. Hypothesis: We aimed to clarify whether V E selectively correlates with marker of vascular stiffness in chronic kidney disease (CKD). Methods: 12 moderate-to-severe CKD pts (mean eGFR 25.9±23.5 mL/min/1.73m 2 ) and 15 controls were studied. Rest V E in brachial artery was measured by new automated oscillometric detector. V E was defined as follows [VE =ΔPressure/ (100XΔarea/Area) mmHg/%]. Using ultrasound, the brachial artery diameter at rest and during reactive hyperemia [flow mediated dilatation (FMD) with endothelial-dependent dilatation] was measured. Gal-3 and interleukin-6 (IL-6), a representative inflammatory marker, were measured by enzyme-linked immune assay. Results: CKD had lower FMD (4.86±3.37 vs 9.05±2.98 %, P=0.003) and had attenuated V E than control (1.08±0.26 vs 0.83±0.17 mmHg/%, P=0.002). CKD had higher IL-6 (0.67±0.29 vs 0.29±0.33 pg/mL, P=0.003) and higher Gal-3 (20.0±12.4 vs. 5.84±2.83 pg/mL, P&lt;0.001). V E was negatively correlated with %FMD (r=-0.46, P=0.015) and correlated with Gal-3 (r=0.40, P=0.036) but not in IL-6 (r=0.21, P=0.28). Conclusions: Attenuated vascular elasticity detected by this novel approach closely correlated with increase in Gal-3 and reduced FMD in CKD. This may indicate that the attenuated vascular elasticity selectively reflects vascular fibrosis as evidenced by Gal-3 and subsequent endothelial responses to vascular stiffness. Thus, this oscillometric measurement may be useful for detecting vascular fibrosis information and dysfunction in endothelium level.